Fig. 5

ERO1α exhibits tumor-promoter activities through the upregulation of SLC7A11. A–E sgERO1α NTC/T1 null cells were infected with lentiviruses carrying an empty vector (vector) or expression vectors for SLC7A11. F–J ERO1α-overexpressing Tsc2 + / + MEFs were infected with lentivirus harboring SLC7A11 shRNAs (shSLC7A11¹ and shSLC7A11.²) or a scrambled shRNA (shSc). CCK-8 (A and F) and EdU (B, C, G and H) assays were performed to evaluate cell proliferation. Scale bar, 50 μm. The effect on angiogenesis was determined by tube formation (D and I) and CAM (E and J) assays. Representative images (left panels) and quantifications (right panels). Scale bar, 50 μm. K–T sgERO1α NTC/T1 null cells, with or without SLC7A11 re-expression (K–O), and ERO1α-overexpressing Tsc2 + / + MEFs, with or without SLC7A11 knockdown (P–T), were subcutaneously injected into nude mice for xenograft assays. K and P Pictures of the removed tumors. L and Q The size of xenograft tumors was measured. M and R Tumors were weighed and plotted. N and S The relative MDA levels of the indicated tumors were measured. O and T Representative IHC images for ERO1α, SLC7A11, Ki-67, and CD31 proteins of the indicated xenograft tumors. Scale bar, 40 μm. Error bars indicate mean ± SD of triplicate (if mentioned otherwise) samples. **P < 0.01; ***P < 0.001; ****P < 0.0001